<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment of metastatic uveal melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment of metastatic uveal melanoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial treatment of metastatic uveal melanoma</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd"><p>This algorithm summarizes our suggested approach to selecting initial therapy in patients with metastatic uveal melanoma. Clinical practice is variable and enrollment in a clinical trial is encouraged, if available. Alternative agents that are not listed may also be effective.</p>
<p>Melanoma brain metastases are rare in uveal melanoma, but their management is complex and may also involve other treatment strategies. Refer to UpToDate content on management of brain metastases in melanoma.</p>
For all patients, we obtain a whole-blood genotyping assay for the presence of HLA-A*02:1, which impacts selection of therapy.</div><div class="graphic_footnotes"><p>HLA: human leukocyte antigen; PHP: percutaneous hepatic perfusion; IHP: isolated hepatic perfusion; OS: overall survival; PFS: progression-free survival; PD-1: programmed cell death protein 1.</p>
<p>¶ Although PFS and objective response rates are modest in patients receiving tebentafusp, this agent improved OS in patients who are HLA-A*02:1 positive, including those whose best treatment response is progressive disease.</p>
<p>Δ Significant extrahepatic disease is defined as tumor burden outside the liver that is extensive enough to require treatment (eg, due to symptoms, tumor bulk, and/or rapidly progressive disease).</p>
<p>◊ Patients with liver-dominant disease may reasonably opt for systemic therapy over locoregional therapy, given the prognosis of this disease and limited data comparing these treatment approaches.</p>
<p>§ Patients who decline or are ineligible for combination nivolumab plus ipilimumab (eg, due to potential toxicity) may alternatively be offered single-agent immunotherapy with a PD-1 inhibitor. We do not typically use chemotherapy or MEK inhibitors due to limited efficacy. Those who are unable to tolerate systemic therapy may be offered best supportive care.</p>
¥ The optimal liver-directed therapy is not known. Selection of therapy is based on clinician and institutional expertise. Most patients with both liver-dominant and limited extrahepatic disease may receive liver-directed therapy followed by systemic therapy. Systemic therapy can be initiated once liver-directed therapy has achieved some degree of hepatic disease control. Alternatively, select patients with low-volume, indolent metastases outside the liver (particularly within the lung) may be observed after completing liver-directed therapy.</div><div id="graphicVersion">Graphic 139783 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
